In light of these findings and because ATM has been linked to controlling DSB resection, a key early step in HRR, it has been suggested that hypersensitivity of ATM-deficient cancer cells to PARP inhibitors, TOP1i, and other S-phase DNA-damaging agents arises from HRD16. This evidence concerns the gene PARP1 and cancer.